Xylo Bio
Also known as: Psylo
Xylo Bio (formerly Psylo) is an Australian-US biotech developing next-generation neuroplasticity-promoting therapeutics for mental health. Founded in 2021 by Josh Ismin and Sam Banister in Sydney, the company has labs at the University of Colorado Boulder and the University of New South Wales. Its lead candidate PSYLO-100X is a non-hallucinogenic compound designed for home administration without clinical supervision, advancing through IND-enabling studies toward first-in-human trials. Xylo has raised $14.2M including an $8M seed round in June 2024 from Tenmile, Focalpoint Partners, and Palo Santo.
Drug Pipeline
1PSYLO-100X
Non-hallucinogenic neuroplasticity compound designed for home administration without clinical supervision; IND-enabling studies underway with goal of first-in-human trials in 2025.
Quick Facts
- Type
- Private Biotech
- Founded
- 2021
- Lead Stage
- Pre-clinical
- Website
- Visit